Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.
About this episode
This episode features an interview with Thomas von Erlach, Ph.D., discussing Vivtex's innovative approach to developing orally available biologics.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas s...
More episodes of Business Of Biotech
- Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
- The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
- Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
- Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
- Investing In Early-Stage Oncology With Yosemite's Dan McHugh
- Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.